- Press Releases
- Notices
Press Releases To List
-
- Nov.20.2025R & D
- Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer
-
- Nov.11.2025R & D
- Updated Global Phase 1/2 Clinical Trial Data for Povetacicept, which was Granted Breakthrough Therapy Designation in IgA Nephropathy and Fast Track Designation in Primary Membranous Nephropathy from FDA
-
- Oct.31.2025Corporate
- Notice on the Recipients of the “Osamu Hayaishi Memorial Scholarship for Study Abroad” of the FY2026 Japanese Biochemical Society
-
- Oct.30.2025Management / Finance
- Announcement on Financial Results for FY2025 Q2
-
- Oct.18.2025R & D
- Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™(vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
Notices To List
-
- Nov.04.2025Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q2 - Script
-
- Sep.29.2025Corporate
- Corporate Report 2025 has been released.
-
- Aug.04.2025Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q1 - Script
-
- Jun.20.2025Corporate
- Voting Results (Extraordinary Report) of the 77th Ordinary General Shareholders’ Meeting
-
- Jun.19.2025Corporate
- Notice to Resolutions Passed at The 77th Ordinary General shareholders’ Meeting
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
